Meibomian Gland

Intense pulsed light therapy and meibomian gland expression improved symptoms in patients with meibomian gland dysfunction, according to a prospective study published in Eye & Contact Lens.

Patients with meibomian gland dysfunction who were treated with an ointment containing selenium sulfide experienced improvement in dry eye symptoms, according to a study.

The FDA has granted de novo authorization to Lumenis for its intense pulsed light device for the management of dry eye disease signs due to meibomian gland dysfunction, according to a press release.

Significant improvement in signs and symptoms of meibomian gland dysfunction were achieved with AZR-MD-001, a topical ointment, thus meeting the primary endpoints of the drug’s phase 2 trial, Azura Ophthalmics announced in a press release.

Here we are on the cusp of a new decade. There are all kinds of new things in literally every pipeline in eye care.

A method to improve meibomian gland structure and complications after amniotic membrane transplantation led January’s cornea/external disease coverage.

Eyes with meibomian gland dysfunction treated with vectored thermal pulsation experienced improved visible meibomian gland structure compared with eyes in a nontreatment control group.

AZR-MD-001, under investigation for the treatment of contact lens discomfort, has reached the primary endpoints in the phase 2 ECLIPTIC study, according to a press release from Azura Ophthalmics.

Patients with obstructive sleep apnea-hypopnea syndrome may experience damage to the meibomian glands and a shortened first noninvasive tear breakup time, which can lead to a predisposition for evaporative dry eye.

With the use of infrared images of the inside of the lower eyelids, researchers determined that higher glucose levels are associated with loss of meibomian glands that are crucial for tear film production, according to study results accepted for presentation at the Endocrine Society Annual Meeting and delivered in a virtual press conference.